The impact of epigenetic modifications on allogeneic hematopoietic stem cell transplantation
YP Ktena, M Dionysiou, LP Gondek… - Frontiers in …, 2023 - frontiersin.org
The field of epigenetics studies the complex processes that regulate gene expression
without altering the DNA sequence itself. It is well established that epigenetic modifications …
without altering the DNA sequence itself. It is well established that epigenetic modifications …
Targeting PRMT1 prevents acute and chronic graft-versus-host disease
X Zhao, Y Sun, Z Xu, L Cai, Y Hu, H Wang - Molecular Therapy, 2023 - cell.com
Graft-versus-host disease (GVHD) is a common complication after allogeneic hematopoietic
stem cell transplantation. Recent studies have reported that protein arginine …
stem cell transplantation. Recent studies have reported that protein arginine …
The pleiotropic roles of EZH2 in T-cell immunity and immunotherapy
Y Wang, T Bui, Y Zhang - International Journal of Hematology, 2022 - Springer
EZH2 is a histone methyltransferase. It catalyzes trimethylation of histone H3 at lysine 27
(H3K27me3) to control gene transcription critical for cell proliferation, differentiation …
(H3K27me3) to control gene transcription critical for cell proliferation, differentiation …
[HTML][HTML] The roles of epigenetic regulation in graft-versus-host disease
Y Wang, Q Liu, L Deng, X Ma, Y Gong, Y Wang… - Biomedicine & …, 2024 - Elsevier
Allogeneic hematopoietic stem cell transplantation (aHSCT) is utilized as a potential curative
treatment for various hematologic malignancies. However, graft-versus-host disease …
treatment for various hematologic malignancies. However, graft-versus-host disease …
Allostimulation leads to emergence of a human B cell population with increased expression of HLA class I antigen presentation–associated molecules and the …
U Bhatia, S Tadman, A Rocha, R Rudraboina… - American Journal of …, 2024 - Elsevier
In the extensive literature characterizing lymphocyte contributions to transplant-related
pathologies including allograft rejection and graft-versus-host disease, T cell–focused …
pathologies including allograft rejection and graft-versus-host disease, T cell–focused …
Assessment of the Therapeutic Potential of Enhancer of Zeste Homolog 2 Inhibition in a Murine Model of Bronchiolitis Obliterans Syndrome
K Matsudo, S Takamori, T Takenaka… - Transplant …, 2024 - frontierspartnerships.org
Bronchiolitis obliterans syndrome (BOS) is a chronic complication following lung
transplantation that limits the long-term survival. Although the enhancer of zeste homolog 2 …
transplantation that limits the long-term survival. Although the enhancer of zeste homolog 2 …
Epigenetics in lymphocyte and lymphoma: EZH2 as an easy-to-access therapeutic target?
K Kato - International journal of hematology, 2022 - Springer
In the epigenetic regulation of gene expression, post-translational modifications such as
phosphorylation, methylation, acetylation, and ubiquitination to DNA and histones that …
phosphorylation, methylation, acetylation, and ubiquitination to DNA and histones that …
GVHD… it is all about the microenvironment!
NJ Chao - Blood, The Journal of the American Society of …, 2022 - ashpublications.org
In this issue of Blood, Zaiken et al describe the impact on chronic graft-versus-host disease
(cGVHD) affecting the formation of germinal centers (GCs) in secondary lymphoid organs …
(cGVHD) affecting the formation of germinal centers (GCs) in secondary lymphoid organs …
Pharmacological targeting EZH2 to modulate chronic graft-versus-host disease
Y Wang - Blood Science, 2022 - journals.lww.com
In a recent issue of Blood (Blood 139, 2022), Zaiken et al 1 reported that in vivo
administration of the EZH2 inhibitor JQ5 effectively reduces chronic graft-versus-host …
administration of the EZH2 inhibitor JQ5 effectively reduces chronic graft-versus-host …
Treatment of graft-versus-host disease with inhibitors of bet family bdii bromodomain
AW Stamford, AM Barsotti, Z Zhang… - US Patent App. 18 …, 2024 - Google Patents
GKHIVNAUVKXIIY-UHFFFAOYSA-N 2-[3-[4-(1h-indazol-5-ylamino) quinazolin-2-yl]
phenoxy]-n-propan-2-ylacetamide Chemical group CC (C) NC (= O) COC1= CC= CC (C …
phenoxy]-n-propan-2-ylacetamide Chemical group CC (C) NC (= O) COC1= CC= CC (C …